when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Pulmonology · news · pharmadog

← back to Pulmonology

News · Pulmonology

515 stories

May 6, 26Clinical Scenario Presentation and Treatment Approach for Progressive Diseaseonclive

May 6, 26Dr Pant on the Mechanism of Action of Daraxonrasib in PDAConclive

May 5, 26Dr Pant on Managing Toxicities With Daraxonrasib in PDAConclive

May 5, 26HS-10504 Shows Promising Activity in EGFR C797S–Mutant NSCLC After TKI Resistanceonclive

May 5, 26Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congressonclive

May 5, 26The Type of Fat—Not the Amount—Fuels Pancreatic Canceronclive

May 5, 26EGFR-Mutated NSCLC: Molecular Reassessment at Disease Progressiononclive

May 5, 26Cytospire hauls in $83M for a new type of T cell engagerbiopharma dive

May 4, 26What to know about hantavirus, the illness suspected in a cruise ship outbreakstat

May 1, 26STAT+: Up and down the ladder: The latest comings and goingsstat

May 1, 26Summit’s ‘self-inflicted’ stumble; Esperion’s take-private dealbiopharma dive

May 1, 26Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlookbiopharma dive

May 1, 26Two biotechs raise a combined $556M in latest spurt of IPOsbiopharma dive

Apr 30, 26Merck still sees ‘compelling’ outlook for Terns leukemia drugbiopharma dive

Apr 30, 26STAT+: What does Akeso’s primo plenary spot say about its survival data?stat

Apr 30, 26Avalyn, in pursuit of better lung drugs, banks $300M in an IPObiopharma dive

Apr 29, 26STAT+: A patent win for Pfizer and BridgeBiostat

Apr 29, 26Opinion: Why alternative medicine can feel so much better than mainstream health carestat

Apr 28, 26STAT+: FDA launches effort to speed up clinical trials, using AIstat

Apr 28, 26Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug developmentstat

Apr 28, 26Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requestsstat

Apr 28, 26FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ resultsbiopharma dive

Apr 28, 26STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data neededstat

Apr 28, 26Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.biopharma dive

Apr 28, 26STAT+: Eli Lilly enlists AI startup for next-generation gene editorsstat

Apr 27, 26New U.S. recommendation on hepatitis B vaccine will have dire consequences, studies projectstat

Apr 27, 26STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapystat

Apr 27, 26Oruka surges as long-acting psoriasis drug shows early promisebiopharma dive

Apr 27, 26What happened to Covid?stat

Apr 24, 26Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drugendpoints

← prevpage 17 of 18next →